The Patent Finder

Santhera Pharmaceuticals (Schweiz) AG

Also on record
Records under this name other than patents Santhera Pharmaceuticals (Schweiz) AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 9 of 9 · Back to Santhera Pharmaceuticals (Schweiz) AG

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,791,289Color Adjustable Lamp
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,716,762Transmucosal Administration System for a Pharmaceutical Drug
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,806,703Transmucosal administration system for a pharmaceutical drug
Held by another company
In force
 · High confidence
In forceHigh confidence
US 7,999,002Use of N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy
Lapsed on the fee record
Ended Aug 16, 2023 · USPTO record
Lapsed on the fee recordEnded Aug 16, 2023USPTO record
US 7,977,388Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies
Lapsed on the fee record
Ended Jul 12, 2023 · USPTO record
Lapsed on the fee recordEnded Jul 12, 2023USPTO record
US 7,078,379Treatment of congenital muscular dystrophies
Term ended
Term ended Feb 28, 2023 · USPTO record
Term endedTerm ended Feb 28, 2023USPTO record
US 7,875,648N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
Lapsed on the fee record
Ended Jan 25, 2023 · USPTO record
Lapsed on the fee recordEnded Jan 25, 2023USPTO record
US 8,293,800Quinone Derivative 2,3-Dimethoxy-5-Methyl-6-(10-Hydroxydecyl)-1,4-Benzoquinone for the Treatment of Primary Progressive Multiple Sclerosis
Formerly held
Lapsed on the fee record
Ended Oct 23, 2020 · High confidence
Lapsed on the fee recordEnded Oct 23, 2020High confidence
US 8,236,818Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
Lapsed on the fee record
Ended Aug 7, 2016 · USPTO record
Lapsed on the fee recordEnded Aug 7, 2016USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited